Transcenta Holding Limited (6628.HK)

1.780 +0.010 (+0.56%) At close: 04:08PM HKT

Transcenta Holding Limited

B6-501, 218 Xinghu Street
Biobay
Suzhou 215123
China
86 21 6237 0929
https://www.transcenta.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 215

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Xueming Qian Ph.D.	CEO & Executive Director	3.52M	N/A	1969
Dr. Feng Ye Ph.D.	Executive VP & COO	N/A	N/A	1969
Dr. Christopher Hwang Ph.D.	Executive VP & CTO	N/A	N/A	1965
Ms. Wei Wang	VP of Investor Relations & Capital Markets Department and Secretary to the Board	N/A	N/A	1983
Dr. Yi Gu Ph.D.	Senior VP & Head of Research	N/A	N/A	1969
Dr. Charlie Qi M.D.	Senior Vice President of Global Clinical Development	N/A	N/A	N/A
Dr. Xichen Zhang Ph.D.	Senior Vice President of Manufacturing	N/A	N/A	N/A
Dr. Wen-I Chang Ph.D.	Senior Vice President of Oncology Franchise Strategy	N/A	N/A	N/A
Dr. Caroline Germa M.D., Ph.D.	Executive VP of Global Medicine Development & Chief Medical Officer	N/A	N/A	1972
Ms. Kwan Wai Leung	Company Secretary	N/A	N/A	1983

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.

Description

Transcenta Holding Limited, a clinical stage biopharmaceutical company, engages in the discovery, research, development, manufacture, and commercialization of various drugs in the People's Republic of China and the United States. The company develops MSB2311, a humanized PD-L1 monoclonal antibody (mAb) candidate for TMB-H solid tumors; TST001, a humanized claudin 18.2 mAb candidate for solid tumors, such as gastric cancer and is under Phase II clinical trial; TST005, a PD-L1/TGF-ß bi-functional antibody candidate which is under Phase Ia clinical trial for solid tumors, including certain lung cancers; TST010, an antibody candidate targeting regulatory T cells to enhance T cell mediated tumor killing;TST002 (Blosozumab), a humanized sclerostin mAb candidate for osteoporosis; and TST004, a humanized mannan-binding lectin serine protease 2 (MASP 2) mAb candidate for IgA kidney diseases. It also develops TST003, an antibody candidate targeting a novel immune regulatory protein produced by tumor-associated fibroblasts or tumor cells with mesenchymal phenotype; TST006, a bi-specific claudin 18.2/PD-L1 antibody; TST008, a tri-functional antibody combining a MASP2 antibody fused with a truncated transmembrane activator and CAML interactor protein; MSB0254, a humanized VEGFR-2 mAb candidate for solid tumors and is under Phase Ib/IIa clinical trials; and MSB2311, A humanized PD-L1 mAb Candidate for solid tumors and is under Phase Ib/IIa clinical trials. It has collaboration agreements with Eli Lilly and Company, Alebund Pharmaceuticals, and Merck, as well as AGILENT Technologies. The company was formerly known as MabSpace International Limited and changed its name to Transcenta Holding Limited in June 2019. Transcenta Holding Limited was incorporated in 2010 and is headquartered in Suzhou, the People's Republic of China.

Corporate governance

Transcenta Holding Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.